BioCorRx Inc.
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Lucido Louis C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Lucido Louis C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BICX / BioCorRx Inc. President, Director, 10% Owner 2,511,940
US:OPP / RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. 0
US:DSL / DoubleLine Income Solutions Fund Secretary 7,325
US:DBL / DoubleLine Opportunistic Credit Fund Secretary 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Lucido Louis C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BICX / BioCorRx Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BICX / BioCorRx Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-01-16 BICX Lucido Louis C. 126 0.7000 126 0.7000 88 84 1.5 101 114.77
2024-01-12 BICX Lucido Louis C. 3,000 0.7000 3,000 0.7000 2,100
2023-04-03 BICX Lucido Louis C. 171,296 1.7500 171,296 1.7500 299,768
2023-01-30 BICX Lucido Louis C. 300 1.3900 300 1.3900 417
2023-01-30 BICX Lucido Louis C. 100 1.3700 100 1.3700 137
2023-01-26 BICX Lucido Louis C. 500 1.2930 500 1.2930 646
2023-01-24 BICX Lucido Louis C. 200 1.2000 200 1.2000 240
2023-01-13 BICX Lucido Louis C. 2,000 1.1000 2,000 1.1000 2,200
2023-01-13 BICX Lucido Louis C. 2,000 1.1500 2,000 1.1500 2,300
2023-01-03 BICX Lucido Louis C. 2,000 1.1000 2,000 1.1000 2,200
2022-12-30 BICX Lucido Louis C. 200 0.9750 200 0.9750 195
2022-12-30 BICX Lucido Louis C. 115 1.0300 115 1.0300 118
2022-12-12 BICX Lucido Louis C. 1,000 0.7900 1,000 0.7900 790
2022-12-12 BICX Lucido Louis C. 1,000 0.9800 1,000 0.9800 980
2022-12-12 BICX Lucido Louis C. 1,000 0.8000 1,000 0.8000 800
2022-12-12 BICX Lucido Louis C. 2,000 0.8000 2,000 0.8000 1,600
2022-10-06 BICX Lucido Louis C. 360 1.9000 360 1.9000 684
2022-10-06 BICX Lucido Louis C. 120 1.9000 120 1.9000 228
2022-10-06 BICX Lucido Louis C. 100 1.7300 100 1.7300 173
2022-10-05 BICX Lucido Louis C. 1,000 2.0200 1,000 2.0200 2,020
2022-09-06 BICX Lucido Louis C. 10 2.1000 10 2.1000 21
2022-08-31 BICX Lucido Louis C. 610 2.1200 610 2.1200 1,293
2022-08-29 BICX Lucido Louis C. 1,000 2.1200 1,000 2.1200 2,120
2022-08-29 BICX Lucido Louis C. 2,268 2.1000 2,268 2.1000 4,763
2022-08-26 BICX Lucido Louis C. 560 2.1200 560 2.1200 1,187
2022-08-25 BICX Lucido Louis C. 500 2.1800 500 2.1800 1,090
2021-10-19 BICX Lucido Louis C. 1,550 3.2000 1,550 3.2000 4,960
2021-02-26 BICX Lucido Louis C. 562,500 2.0000 562,500 2.0000 1,125,000
2021-01-22 BICX Lucido Louis C. 2,000 1.4400 2,000 1.4400 2,880
2019-04-03 BICX Lucido Louis C. 200,000 15.0000 200,000 15.0000 3,000,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BICX / BioCorRx Inc. Insider Trades
Insider Sales BICX / BioCorRx Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BICX / BioCorRx Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BICX / BioCorRx Inc. Insider Trades
Insider Purchases DBL / DoubleLine Opportunistic Credit Fund - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BICX / BioCorRx Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DBL / DoubleLine Opportunistic Credit Fund Insider Trades
Insider Sales DBL / DoubleLine Opportunistic Credit Fund - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BICX / BioCorRx Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DBL / DoubleLine Opportunistic Credit Fund Insider Trades
Insider Purchases DSL / DoubleLine Income Solutions Fund - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BICX / BioCorRx Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2013-09-06 DSL Lucido Louis C. 7,325 20.4999 7,325 20.4999 150,162 279 22.65 15,750 10.49

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DSL / DoubleLine Income Solutions Fund Insider Trades
Insider Sales DSL / DoubleLine Income Solutions Fund - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BICX / BioCorRx Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

DSL / DoubleLine Income Solutions Fund Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Lucido Louis C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-01-31 2024-12-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 13,158 2,511,940 0.53
2025-01-31 2024-12-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 43,860 2,498,782 1.79
2025-01-31 2024-11-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 55,494 2,454,922 2.31
2025-01-31 2024-10-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 55,556 2,399,428 2.37
2025-01-31 2024-10-14 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,105,218 2,343,872 89.23
2025-01-31 2024-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 15,625 1,238,654 1.28
2025-01-31 2024-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 52,085 1,223,029 4.45
2025-01-31 2024-08-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 55,559 1,170,944 4.98
2025-01-31 2024-07-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 32,092 1,115,385 2.96
2025-01-31 2024-04-24 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		J - Other 460,477 1,083,293 73.93
2024-07-10 2024-06-28 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 34,016 622,816 5.78
2024-07-10 2024-06-28 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 10,204 588,800 1.76
2024-06-03 2024-05-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 22,831 578,596 4.11
2024-05-01 2024-04-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 21,552 555,765 4.03
2024-04-03 2024-03-28 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 18,553 534,213 3.60
2024-04-03 2024-03-28 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 5,566 515,660 1.09
2024-03-07 2024-02-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 16,892 510,094 3.42
2024-03-07 2024-01-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 18,269 493,202 3.85
2024-01-17 2024-01-16 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 126 474,933 0.03 0.70 88 332,453
2024-01-17 2024-01-12 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 3,000 474,807 0.64 0.70 2,100 332,365
2024-01-04 2024-01-02 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 6,173 471,807 1.33
2023-10-02 2023-09-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,858 465,634 0.62
2023-07-05 2023-06-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,891 462,776 0.63
2023-04-05 2023-04-03 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		J - Other 183,606 459,885 66.46
2023-04-05 2023-04-03 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 171,296 276,279 163.17 1.75 299,768 483,488
2023-04-03 2023-03-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,824 104,983 2.76
2023-01-31 2023-01-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 100 102,159 0.10 1.37 137 139,958
2023-01-31 2023-01-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 300 102,059 0.29 1.39 417 141,862
2023-01-27 2023-01-26 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 500 101,759 0.49 1.29 646 131,574
2023-01-25 2023-01-24 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 200 101,259 0.20 1.20 240 121,511
2023-01-17 2023-01-13 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 2,000 101,059 2.02 1.15 2,300 116,218
2023-01-17 2023-01-13 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 2,000 99,059 2.06 1.10 2,200 108,965
2023-01-04 2023-01-03 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 2,000 97,059 2.10 1.10 2,200 106,765
2023-01-04 2022-12-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 5,319 95,059 5.93
2023-01-04 2022-12-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 115 89,740 0.13 1.03 118 92,432
2023-01-04 2022-12-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 200 89,625 0.22 0.98 195 87,384
2022-12-15 2022-12-12 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 2,000 89,425 2.29 0.80 1,600 71,540
2022-12-15 2022-12-12 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,000 87,425 1.16 0.80 800 69,940
2022-12-15 2022-12-12 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,000 86,425 1.17 0.98 980 84,696
2022-12-15 2022-12-12 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,000 85,425 1.18 0.79 790 67,486
2022-10-11 2022-10-06 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 100 84,425 0.12 1.73 173 146,055
2022-10-11 2022-10-06 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 120 84,325 0.14 1.90 228 160,218
2022-10-11 2022-10-06 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 360 84,205 0.43 1.90 684 159,990
2022-10-11 2022-10-05 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,000 83,845 1.21 2.02 2,020 169,367
2022-10-11 2022-09-06 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 10 82,845 0.01 2.10 21 173,974
2022-10-05 2022-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,450 82,835 3.05
2022-08-31 2022-08-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 610 80,385 0.76 2.12 1,293 170,416
2022-08-31 2022-08-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 2,268 79,775 2.93 2.10 4,763 167,528
2022-08-31 2022-08-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,000 77,507 1.31 2.12 2,120 164,315
2022-08-29 2022-08-26 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 560 76,507 0.74 2.12 1,187 162,195
2022-08-29 2022-08-25 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 500 75,947 0.66 2.18 1,090 165,564
2022-07-07 2022-06-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,092 75,447 2.85
2022-04-04 2022-03-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,408 73,355 1.96
2022-03-02 2021-12-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,141 71,947 1.61
2021-10-25 2021-10-19 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 1,550 70,806 2.24 3.20 4,960 226,579
2021-10-25 2021-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,381 68,536 2.06
2021-07-14 2021-06-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,210 67,155 1.83
2021-04-02 2021-03-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,315 65,945 3.64
2021-03-02 2021-02-26 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 per share 		P - Purchase 562,500 562,500 2.00 1,125,000 1,125,000
2021-03-02 2021-01-22 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 per share 		P - Purchase 2,000 63,630 3.25 1.44 2,880 91,627
2021-01-05 2020-12-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 4,901 261,926 1.91
2020-10-13 2020-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,631 257,025 1.03
2020-07-01 2020-06-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,761 254,394 0.70
2020-04-02 2020-03-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 2,641 252,633 1.06
2020-01-13 2019-12-31 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,818 249,992 0.73
2019-10-10 2019-09-30 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,587 248,174 0.64
2019-07-08 2019-06-28 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,176 246,587 0.48
2019-04-04 2019-04-03 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		P - Purchase 200,000 245,411 440.42 15.00 3,000,000 3,681,165
2019-04-02 2019-03-29 4 BICX BioCorRx Inc.
Common Stock, par value $0.001 		A - Award 1,241 45,411 2.81
2019-03-11 3 BICX BioCorRx Inc.
Common Stock, par value $0.001 per share 		87,748
2019-03-11 3 BICX BioCorRx Inc.
Common Stock, par value $0.001 per share 		87,748
2019-03-11 3 BICX BioCorRx Inc.
Common Stock, par value $0.001 per share 		87,748
2016-09-27 3 OPP RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.
Common Stock 		0
2013-09-06 2013-09-06 4 DSL DoubleLine Income Solutions Fund
Common Stock 		P - Purchase 7,325 7,325 20.50 150,162 150,162
2013-04-25 3 DSL DoubleLine Income Solutions Fund
Common Stock 		0
2012-01-26 3 DBL DoubleLine Opportunistic Credit Fund
Common Stock 		0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)